24/7 Market News- Tenax Therapeutics Enters Oversubscribed $100 M PP

DENVER, Colo., Aug 06, 2024 (247marketnews.com)- Tenax Therapeutics, Inc. (Nasdaq: TENX) stated that it entered into an oversubscribed private placement financing, which is expected to generate approximately $100 million in total gross proceeds to Tenax, before deducting placement agent fees and other private placement expenses.

The Company plans to use the net private placement proceeds to complete its ongoing Phase 3 LEVEL trial, to initiate all sites and advance enrollment in a second planned Phase 3 trial of oral levosimendan, and for working capital, capital expenditures, and other general corporate purposes. Tenex believes that it will have enough to fund the Company’s operations through the end of 2027.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (TENX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.